Breaking up with Pfizer is hard to do, Zoetis chief says, but worth it

Why do Russians prefer cats to dogs? Which livestock drugs are growing fastest? And what are the benefits of being separate from Pfizer? Juan Ramón Alaix, CEO of the Zoetis ($ZTS) animal health business Pfizer ($PFE) spun off early this year, answers these and other questions in a Wall Street Journal interview. Report (sub. req.)

Suggested Articles

Pfizer will exit its Perth, Australia sterile injectables manufacturing site by 2024 as part of a global production reorganization effort.

Agios has withdrawn a European application for Tibsovo in AML after the same phase 1 data that earned it an FDA nod failed to impress the EMA.

Sanofi is reportedly considering a sale of some of its anti-inflammation drugs that could snare $234 million as the company pivots toward Dupixent.